Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular DegenerationGlobeNewsWire • 07/29/26
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial ResultsGlobeNewsWire • 07/28/26
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaGlobeNewsWire • 07/13/26
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage CareZacks Investment Research • 06/03/26
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?Zacks Investment Research • 06/03/26
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesGlobeNewsWire • 05/14/26
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookZacks Investment Research • 05/06/26
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior NotesGlobeNewsWire • 05/05/26
Ocugen Announces Private Offering of $115 Million of Convertible Senior NotesGlobeNewsWire • 05/04/26
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial ResultsGlobeNewsWire • 04/29/26